Rossari Biotech Share Price

Rossari Biotech Limited is a leading specialty chemicals manufacturer in India, engaged in the production and sale of a wide range of chemical products for diverse end-user industries. The company operates through three segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health and Nutrition (AHN). Rossari Biotech has a strong presence in both domestic and international markets, exporting to over 60 countries worldwide. The Rossari Biotech share price today on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Rossari Biotech stock price often mirrors shifts in demand from downstream industries like textiles, home and personal care, and animal health, as well as investor views on the specialty chemicals sector’s growth prospects. Factors such as the pace of capacity expansion, competitive intensity from domestic and international players, raw material cost inflation, and government policies on chemical manufacturing influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Rossari Biotech stock price movements.

Rossari Biotech live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Rossari Biotech live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Rossari Biotech price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Rossari Biotech Limited Company Fundamentals

a. Company Background

Rossari Biotech Limited was incorporated in 2009. The company’s registered office is located in Mumbai, Maharashtra, India. The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. The company was founded in 1997 and is based in Mumbai, India. Rossari Biotech’s primary activity involves the manufacturing, selling, and distribution of specialty chemicals across three segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health and Nutrition (AHN). It initially focused on textile chemicals before gradually expanding into home care, personal care, performance chemicals, and animal health and nutrition. Over the years, Rossari Biotech has significantly expanded its manufacturing capacity, with the full commissioning of its Greenfield manufacturing facility at Dahej, Gujarat. The company operates in a competitive environment, with its products catering to industries including soaps and detergents, inks, paints and coatings, ceramics and tiles, pulp and paper, cement, water treatment, and animal feed.

b. Product Lines

• Home, Personal Care and Performance Chemicals (HPPC) including specialty surfactants, phenoxy series, institutional cleaning chemicals, acrylic polymers, and performance additives for improving appearance, texture, and processability

• Textile Specialty Chemicals (TSC) including auxiliaries, finishing agents, and processing chemicals for textile manufacturing

• Animal Health and Nutrition (AHN) products including enzymes (xylanase, phytase), feed additives, and nutritional supplements for poultry and livestock

• Soaps and detergents chemical formulations for cleaning applications

• Inks, paints, and coatings additives for printing and surface finishing

• Ceramics and tiles processing chemicals for manufacturing

• Pulp and paper chemicals including binders and resins

• Cement additives and water treatment solutions

• Cleaning chemical formulations for institutional and industrial cleaning applications

c. Company Revenue Model

• Primary revenue from the sale of specialty chemicals across three business segments: HPPC (contributing 76-77% of revenues), TSC, and AHN

• Revenue from domestic sales to customers across India including textile mills, home care product manufacturers, and animal feed producers

• Income from export sales to international markets including over 60 countries worldwide

• Fee-based income from contract manufacturing and toll processing arrangements

• Revenue from value-added technical services and customer support for chemical applications

• Processing fees and service charges on chemical formulations and custom blending

• Seasonal variations in demand for textile chemicals and home care products affecting revenue patterns throughout the year

• Government policy changes on chemical manufacturing and international trade influencing revenue stability

d. Geographic Presence

• Strong presence across India with manufacturing facilities in Dahej, Gujarat (Greenfield facility) and other locations

• Registered office and headquarters located in Mumbai, Maharashtra

• Export presence in over 60 countries worldwide through international distribution networks

• Operations primarily concentrated in India, with growing international footprint through exports

• Digital platform enabling customer acquisition across domestic and international markets

• Focus on expanding international presence, with exports rising as a percentage of total revenue

e. Key Milestones

• 1997: Business commenced as a partnership firm in the name of Rossari Labtech

• 2003: Incorporated as Rossari Biotech Limited in December

• 2009: Registered as a public limited company

• 2020: IPO opened for subscription from July 13 to July 15, 2020, at price band of ₹423-425 per share, with issue size of ₹496 crore

• 2020: Shares listed on NSE and BSE on July 23, 2020

• 2021: Announced full commissioning of Greenfield manufacturing facility at Dahej, Gujarat

• 2021: Completed acquisition of 76% stake in Tristar Intermediates

• 2025: Successfully diversified revenue streams across all business segments

f. Industry Perspective

Rossari Biotech Limited operates in the specialty chemicals industry. Globally, the specialty chemicals market was valued at approximately USD 600 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 5-6% from 2025 to 2030, driven by increasing demand from end-user industries including pharmaceuticals, agrochemicals, and personal care. In India, the specialty chemicals sector is poised for substantial growth. According to IMARC Group, the India specialty chemicals market reached USD 67.0 billion in 2025 and is expected to reach USD 93.4 billion by 2034, exhibiting a CAGR of 3.65% during 2026-2034. India’s specialty chemicals market is anticipated to grow at a CAGR of 12 percent, reaching $64 billion by 2025 according to industry reports. Specialty chemistries currently account for 20% of total global chemistries worth $4 trillion. India’s chemical market is currently valued at USD 220 billion and is projected to reach USD 383 billion by 2030, reflecting a CAGR of 8.1% from 2021 to 2030. The textile chemicals segment, where Rossari Biotech is a leader, is growing at 8-10% annually. Demand is driven by increasing consumption of home and personal care products, growth in textile manufacturing, and rising awareness of animal health and nutrition. Key challenges include raw material price volatility, intense competition from domestic and international players, and environmental compliance costs.

Rossari Biotech Limited Stock Market Presence: Listings & Index Representation

Rossari Biotech is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol ROSSARI and on the Bombay Stock Exchange (BSE) with the scrip code 543213. Its listing on both exchanges ensures that the Rossari Biotech share price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company was listed on July 23, 2020, through an initial public offering (IPO) at an issue price of ₹423-425 per share. The company forms part of several benchmark indices that represent broad market segments. Rossari Biotech is included in indices such as BSE 500, BSE AllCap, BSE SmallCap, BSE Commodities, and Nifty 500 on the NSE. Being represented in multiple indices enhances the visibility and liquidity of the Rossari Biotech stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s specialty chemicals landscape. The inclusion of Rossari Biotech in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the stock price to corporate and industry developments.

Rossari Biotech Limited Stock Performance and Share Price History

The Rossari Biotech price has exhibited significant volatility over the past five years since its IPO, shaped by the company’s growth in the specialty chemicals sector and broader market conditions. The Rossari Biotech share price recorded a negative total return of approximately 19.67% over the last 1 year and a negative return of 22.73% over the last 3 years, underperforming broader market indices and reflecting near-term headwinds including raw material cost pressures and valuation concerns. The Rossari Biotech share price delivered a 5-year total return of 5.42% since its IPO, demonstrating modest long-term wealth creation. The Rossari Biotech share price reached a 52-week high of ₹766.00 and a 52-week low of ₹375.00, indicating a wide trading range and substantial price fluctuations of approximately ₹391 from peak to trough. The Rossari Biotech share price recorded a strong rally in 2021 following its IPO, while the subsequent period has seen the Rossari Biotech stock price correct significantly from its peak levels. The Rossari Biotech share price has shown a 1-month return of approximately -4.5% to -9.5% and a 6-month return of -27.28% as of April 2026, indicating recent consolidation.

The Rossari Biotech price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 4.39% rise in net profit to ₹36.88 crore in Q2 FY26 and a 3.38% rise to ₹32.77 crore in Q3 FY26, the Rossari Biotech stock price showed a muted reaction. The Rossari Biotech price has shown a pattern of positive momentum when the company announced capacity expansions and new product launches, while periods of earnings moderation or concerns over raw material costs have contributed to consolidation in the Rossari Biotech stock price. Corporate developments, including strategic announcements such as the commissioning of the Dahej Greenfield facility, the acquisition of a 76% stake in Tristar Intermediates, and the company’s focus on diversifying revenue streams across all segments, have also influenced short-term fluctuations in the Rossari Biotech price. The Rossari Biotech share price has shown a 5-year return of 5.42% since its IPO date, reflecting the volatility in the stock. The Rossari Biotech share price reached its 52-week high of ₹766.00 before declining to its 52-week low of ₹375.00, reflecting the volatility inherent in the specialty chemicals space. The Rossari Biotech share price has shown a year-to-date return of approximately -25% to -30% as of April 2026, indicating continued pressure in the current fiscal year. Comprehending these patterns in the Rossari Biotech share price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Rossari Biotech stock price movements illustrate how industry fundamentals, raw material cycles, and investor expectations converge in market pricing.

The Rossari Biotech share price has shown distinct seasonal patterns over the past five years. In terms of annual performance, the Rossari Biotech share price delivered its strongest annual returns in 2021 following its IPO, while the stock recorded negative annual returns in 2022, 2023, 2024, and 2025. The Rossari Biotech share price has demonstrated that the stock tends to perform better in periods of strong specialty chemicals demand and favorable international pricing, while underperforming during phases of input cost inflation and intense competition from domestic and international players.

Rossari Biotech Limited Investor Relevance and Role in Portfolio

Rossari Biotech holds a significant position for portfolio investors who seek exposure to India’s specialty chemicals sector with a focus on diversified end-user industries. The company’s diversified product portfolio across HPPC, textile specialty chemicals, and animal health and nutrition aligns it with investment strategies that value manufacturing scale, product innovation, and export growth. The Rossari Biotech share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor capacity expansion metrics and export growth indicators when evaluating allocation decisions.

Institutional stakeholders play a significant role in Rossari Biotech’s ownership profile, with notable long term investment entities such as SBI Mutual Fund, HDFC Mutual Fund, Nippon Life India Asset Management Limited, ICICI Prudential Asset Management Company Limited, Kotak Mahindra Asset Management Company Limited, Axis Mutual Fund, Motilal Oswal Asset Management Company Limited, UTI Asset Management Company Limited, Franklin Templeton Mutual Fund, and Mirae Asset Global Investments Co., Ltd. among key shareholders identified in institutional holdings data. Mutual fund holders of Rossari Biotech encompass those that seek chemicals and manufacturing exposure, including SBI Small Cap Fund (holding 0.28% to 0.33% as of recent data), and other mutual funds as per shareholding data. As of December 2025, mutual funds held 13.47% stake, Foreign Institutional Investors held 2.33%, and Domestic Institutional Investors held 4.78% of Rossari Biotech. Promoter holding stands at 68.16% as of December 2025. These investors represent a blend of domestic and institutional perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks.

The beta analysis of Rossari Biotech across multiple time periods highlights its changing volatility in relation to the overall market. Based on data, the long-term beta (5-year monthly) stands at approximately 0.23, indicating that the stock is significantly less volatile than the broader market over an extended period. In short-term analysis, beta values over the one-year range of 0.57 to 0.92 show low sensitivity to market fluctuations. Weekly data reveals beta of 0.26 showing the stock’s low sensitivity to weekly market changes, with weekly volatility (4%) having been stable over the past year. The average weekly movement of Rossari Biotech stock is approximately 4.0%, compared to the chemicals industry average of 5% and the market average of 6%, indicating relatively lower volatility than both its industry and the broader market. The daily price range percentages are: 3-day at 2.0%, 5-day at 2.5%, 10-day at 3.0%, 15-day at 3.5%, 35-day at 4.0%, and 50-day at 4.5%, indicating moderate intra-period volatility. The stock is 1.06% volatile according to recent data. The Rossari Biotech share price has shown periods of heightened responsiveness to sector-specific news and quarterly earnings releases. The Rossari Biotech stock price’s low beta reflects that the company’s established market position and diversified product portfolio may provide some stability, though the specialty chemicals sector remains sensitive to raw material cost fluctuations and international trade dynamics.

Rossari Biotech Limited Sectoral Relevance and Peer Positioning

The sector relevance of Rossari Biotech is anchored in its role within the broader Indian specialty chemicals industry, where it competes with other diversified chemical manufacturing companies. As part of this industry, the company’s strategic positioning connects specialty chemicals to downstream industries including textiles, home and personal care, paints and coatings, and animal health and nutrition. Competitors in the specialty chemicals segment include companies such as Arkema, Clariant, Scimplify, Kronox Lab Sciences, Aquapharm, Calibre, Navin Fluorine International Limited, Himadri Speciality Chemical Limited, Deepak Nitrite Limited, Fineotex Chemical Limited, and other domestic and international players. Firms with parallels in either product portfolio scale or end-user industry diversification are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Rossari Biotech P/E ratio have shown variations over different periods. The current P/E ratio of Rossari Biotech stands at approximately 16.16 to 31.22 times, representing a discount to its historical averages. The Rossari Biotech P/E ratio has shown fluctuations since its IPO, with the ratio at 16.16 in recent data, compared to higher levels of 31.22 in other periods, reflecting changing investor perceptions of the company’s earnings potential.

Similarly, the Rossari Biotech EPS narrative has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from capacity expansion and product diversification supported directional improvement in earnings per share during favourable conditions, while cyclical headwinds from raw material inflation and softer demand phases have moderated EPS momentum. Rossari Biotech earnings have shown a trajectory that responded to both revenue growth and margin pressures over the analysed period. Rossari Biotech market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and evolving specialty chemicals market, currently standing at approximately ₹2,448 crore to ₹2,735 crore.

• Market Cap History
  Over the last five years since its IPO in July 2020, the market capitalisation of Rossari Biotech has followed a pattern of growth followed by moderation. The company’s market cap showed an increasing trend post-IPO, reflecting strong investor confidence. The market cap increased from ₹2,271 crore in recent periods to approximately ₹2,448 crore to ₹2,735 crore as of 2026. According to data, market cap stood at ₹3,123 crore as of February 2026, with a one-year decrease of 20.05%. Historical market cap data shows ₹2,271 crore at some periods, ₹3,212 crore at others, ₹3,818 crore, ₹3,344 crore, ₹4,287 crore, and a peak of ₹5,017 crore at certain points. This decrease mirrors the correction in the Rossari Biotech share price and the broader underperformance of the specialty chemicals sector relative to broader market indices.
• Earnings History
  The earnings history of Rossari Biotech over the past five years has been characterised by a period of growth followed by recent moderation. Net income showed a generally increasing trend, with reported net profit rising from ₹99.64 crore in FY2024 to ₹114.74 crore in FY2025, a 15.15% increase. For the trailing twelve months, net profit stands at approximately ₹100-115 crore. Quarterly performance showed net profit of ₹36.88 crore in Q2 FY26 (up 4.39% YoY), ₹32.77 crore in Q3 FY26 (up 3.38% YoY), and ₹33 crore in Q3 FY26 according to some sources. Revenue in Q3 FY26 stood at ₹582 crore with margins of 11.8%. This consistent earnings performance reflects the impact of capacity expansion, product diversification, and operational efficiency on the company’s profitability.
• EPS History
  The Earnings Per Share (EPS) history for Rossari Biotech has shown variation over the past five years. The diluted EPS growth rate has shown fluctuation, with EPS at ₹24.62 in recent data, compared to ₹25.09 in other periods. Over a five-year period since IPO, the company demonstrated mixed EPS performance, with average earnings per share growth of approximately 10-15% per year in recent years. The current TTM EPS stands at approximately ₹24.62.
• P/E History
  The Price-to-Earnings (P/E) ratio history of Rossari Biotech has shown fluctuations over the five-year period. At the end of recent fiscal years, the P/E ratio varied, with the ratio at 16.16 in recent data, compared to 18.13, 20.00, 21.52, and 31.22 in other periods. The mean historical P/E ratio over the last five years has been around 20-25 times. The current P/E ratio stands at a discount to the industry peer median of 26-30 times, reflecting that investor expectations are adjusting to near-term earnings headwinds. The Rossari Biotech share price has been influenced by these valuation metrics. The Rossari Biotech stock price continues to be evaluated in the context of its earnings potential and market position.

Summary

Rossari Biotech is a leading specialty chemicals company in India listed on both the NSE and BSE, where the Rossari Biotech share price reflects demand from textiles, home care, and animal health sectors, raw material cost dynamics, and capacity expansion within the specialty chemicals industry. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader chemical manufacturing themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s specialty chemicals market.